

Performance Against Initiation Benchmark

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
16/SC/0350	199995	Does a ketogenic diet reduce delirium in Intensive Care. Part I - A feasibility study to test if a ketogenic diet causes ketosis in patients on	04/02/2016	20/02/2017	20/02/2017	20/02/2017	21/02/2017	01/04/2017	17/06/2017	NHS Provider
16/EE/0463	214371	CompLEEment-1	08/08/2016	20/01/2017	30/01/2017	30/01/2017	21/02/2017	15/03/2017	30/03/2017	Benchmark Met
17/LO/0017	213632	Open-label Extension Study for Participants with Prostate Cancer	05/08/2016	15/02/2017	08/03/2017	09/03/2017	13/03/2017	15/06/2017	11/07/2017	Sponsor
16/LO/1322	208946	RSV-M-301	31/08/2016	28/03/2017	09/09/2016	05/04/2017	06/04/2017	08/05/2017	03/07/2017	Sponsor
16/EM/0512	215840	TRIOLOGY	06/01/2017	04/04/2017	28/02/2017	05/04/2017	20/04/2017	21/04/2017	02/05/2017	Benchmark Met
16/WS/0197	186191	ATLANTIS	23/03/2017	23/03/2017	01/02/2017	13/04/2017	21/04/2017	28/06/2017	28/11/2017	Neither
16/EE/0421	209972	Athena	02/09/2016	10/03/2017	13/01/2017	23/01/2017	27/04/2017			Sponsor
16/EE/0325	204922	Venetoclax (ABT-199) in relapsed/refractory CLL (M15-550)	14/09/2016	06/03/2017	28/09/2016	02/05/2017	04/05/2017	10/05/2017	23/05/2017	Sponsor
16/NW/0517	188554	Myeloma XII (ACCoRd trial) Version 1.0	01/11/2016	09/05/2017	27/10/2016	12/05/2017	22/05/2017	22/05/2017		Neither
16/NE/0142	202233	CANC 5578 (B9991010)	05/05/2017	05/05/2017	01/11/2016	10/05/2017	23/05/2017	25/05/2017	25/09/2017	NHS Provider
17/SC/0055	219468	AIN457 Paed	18/05/2017	22/05/2017	21/03/2017	22/05/2017	23/05/2017	30/05/2017	01/06/2017	Benchmark Met
17/EE/0079	220827	CL010_168	25/01/2017	20/04/2017	06/04/2017	19/06/2017	22/06/2017	30/06/2017		Neither
16/YH/0157	204585	PLATO - PersonaLising Anal cancer radioTherapy	08/06/2017	08/06/2017	20/07/2016	13/06/2017	23/06/2017	26/06/2017	04/07/2017	Benchmark Met
16/ss/0014	187949	GEM3	18/05/2017	14/06/2017	14/10/2016	30/06/2017	30/06/2017	14/09/2017	01/12/2017	Both
17/LO/0035	218519	ACTiF - RCT and parallel process evaluation (WP 3.2 and 3.3)	06/01/2017	16/05/2017	03/04/2017	16/05/2017	20/07/2017	18/09/2017	19/10/2017	Sponsor
17/SW/0127	225959	Flight-A multicentre randomised trial of First Line treatment pathways for newly diagnosed Immune Thrombocytopenia: Standard steroid treatment versus combined steroid and	15/05/2017	19/06/2017	03/07/2017	19/06/2017	19/06/2017	26/10/2017	06/11/2017	Sponsor
16/LO/1222	191705	ATLANTIS Trial	17/10/2016	12/05/2017	05/05/2017	13/07/2017	17/07/2017	11/08/2017		Neither
17/EM/0063	213979	230075	12/01/2016	19/04/2017	27/04/2017	31/08/2017	31/08/2017	08/09/2017		Sponsor
16/NE/0325	199217	ECUSTEC	16/09/2016	05/06/2017	30/05/2017	13/07/2017	14/07/2017	02/08/2017	21/09/2017	Neither
17/NE/0117	222778	Osteogenesis Imperfecta 3082/0003 Mereo	20/01/2017	22/06/2017	25/08/2017	11/07/2017	18/07/2017	25/09/2017		Sponsor
17/SC/0142	215503	The 65 Trial (v1.0)	20/03/2017	07/07/2017	24/04/2017	11/07/2017	17/07/2017	31/07/2017	08/09/2017	Benchmark Met
16/YH/0452	130824	VINILO	16/08/2016	04/05/2017	09/12/2016	09/05/2017	09/05/2017	10/05/2017	03/07/2017	Benchmark Met
17/NW/0022	219189	Post-Authorization Study of HyQvia in Pediatric PID subjects	09/01/2017	27/06/2017	06/03/2017	27/07/2017	27/07/2017	08/08/2017	14/08/2017	Benchmark Met
17/SC/0083	218035	CV185362 Pediatric Anticoagulation for Prevention of Thromboembolism	03/02/2017	10/04/2017	07/07/2017	13/07/2017	27/07/2017	23/08/2017	20/09/2017	Sponsor
17/SC/0039	220282	MAGPIE	03/05/2017	05/07/2017	18/04/2017	07/07/2017	11/07/2017	07/08/2017	14/08/2017	Benchmark Met
16/LO/2141	200571	Biomede	06/06/2017	07/07/2017	06/04/2017	07/07/2017	07/07/2017	12/07/2017	27/07/2017	Benchmark Met
16/NW/0629	211995	CF START	15/08/2017	08/09/2017	22/09/2016	05/10/2017	05/10/2017	14/12/2017		Sponsor
17/NW/0223	219119	Evaluation of PKU explore	08/08/2017	07/09/2017	22/04/2017	14/09/2017	14/09/2017	29/09/2017	24/10/2017	Benchmark Met

Performance Against Initiation Benchmark

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
17/EM/0075	222172	High Energy High Protein Tube Feed Study	27/02/2017	27/03/2017	27/03/2017	09/05/2017	11/05/2017	15/05/2017	26/05/2017	Benchmark Met
16/ES/0110	207747	TOPaZ study	13/01/2017	13/01/2017	12/01/2017	01/03/2017				Sponsor
16/LO/1457	199790	HEPA 5188	01/02/2017	16/05/2017	12/10/2016	21/06/2017	19/09/2017	21/09/2017	10/10/2017	NHS Provider
16/EM/0194	194984	DERM 5311	24/08/2016	06/06/2017	24/06/2016	12/06/2017	12/06/2017	03/07/2017	03/08/2017	Benchmark Met
16/NE/0316	207651	Phase 1 Study CYP-001 for the Treatment of Acute Graft vs Host Disease	11/01/2017	28/02/2017	12/12/2016	06/05/2017	09/05/2017	09/05/2017	10/05/2017	Sponsor
17/EM/0152	216307	Post-transplant Gilteritinib maintenance in acute myeloid leukaemia	19/10/2016	15/09/2017	21/07/2017	06/12/2017	15/12/2017			Sponsor
17/LO/0038	182633	UK P3BEP Trial	22/05/2017	22/09/2017	06/04/2017	05/10/2017	13/10/2017	18/10/2017		Neither
16/YH/0450	213782	20150288 - Blinatumomab in DLBCL	06/02/2017	10/03/2017	25/01/2017	12/07/2017	18/07/2017	25/07/2017		Sponsor
16/WS/0089	197457	PARADIGM-2	09/06/2017	27/07/2017	16/12/2016	02/08/2017	15/08/2017	31/08/2017	11/09/2017	Benchmark Met
17/LO/0023	215490	MUK nine b: OPTIMUM	12/01/2017	30/08/2017	30/03/2017					Both
17/LO/0249	220398	CO39385: Study of Atezolizumab + Enzalutamide vs Enzalutamide in mCRPC	16/06/2017	13/07/2017	28/04/2017	10/08/2017	22/08/2017	16/11/2017		Sponsor
17/SC/0228	219158	Javelin Head and Neck	16/12/2016	02/08/2017	24/07/2017	24/11/2017	05/12/2017			Both
16/WS/0165	190574	ADSCaN.	19/07/2017	02/08/2017	13/02/2017	31/08/2017	28/09/2017	22/12/2017		Sponsor
17/WA/0087	222840	The Caravaggio Study	26/06/2017	14/09/2017	06/07/2017	06/10/2017	10/10/2017	12/10/2017	10/11/2017	Benchmark Met
17/LO/1174	229691	Phase 2 of Filgotinib in patients with active non-infectious uveitis	19/06/2017	27/09/2017	22/08/2017	28/10/2017	30/11/2017	04/12/2017		Both
17/WM/0110	212527	PHITT	28/06/2017	12/10/2017	28/04/2017	29/11/2017	29/11/2017	29/11/2017	30/11/2017	Benchmark Met
16/SC/0271	187103	plasmaMATCH	16/06/2017	16/10/2017	21/09/2016	10/11/2017	15/11/2017	24/11/2017	27/11/2017	Benchmark Met
16/LO/0680	186642	SMILE (PENTA 17)	10/11/2016	09/11/2017	28/07/2016	21/12/2017				Not yet 70 days
17/LO/1656	229212	IMspire 170	18/08/2017	09/11/2017	14/11/2017	22/11/2017	05/12/2017	11/12/2017		Not yet 70 days
17/LO/1865	232414	IKEMA (EFC15246) - Combination therapy with isatuximab in patients with multiple myeloma	11/04/2017	10/11/2017	13/12/2017					Not yet 70 days
17/SW/0174	228278	CANC 35573	11/09/2017	16/11/2017						Not yet 70 days
17/NE/0151	223815	SGL-110 vs Treatment Choice in Adults with Previously Treated AML	24/08/2017	21/11/2017	19/07/2017					Not yet 70 days
17/YH/0392	230501	BI 1467335 in patients with diabetic retinopathy.	04/08/2017	13/12/2017						Not yet 70 days
17/NW/0333	223199	Faecal volatiles in children with inflammatory bowel disease	14/09/2017	15/09/2017	18/07/2017	10/11/2017	10/11/2017	14/11/2017	21/11/2017	Benchmark Met
16/NS/0106	212541	RAACENO	11/10/2017	11/10/2017	04/04/2017	19/10/2017	24/11/2017	13/12/2017		Sponsor
17/LO/0334	214459	FLO-ELA	16/11/2017	24/11/2017	29/03/2017					Not yet 70 days
17/EM/0301	209448	The SANDWICH Trial	04/08/2017	05/12/2017	29/09/2017	14/12/2017	14/12/2017			Not yet 70 days